CB-13

CB-13 (CRA13, SAB-378)^[1] is a cannabinoid drug, which acts as a potent agonist at both the CB₁ and CB₂ receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,^[2] and has progressed to preliminary human trials.^[3]

CB-13

Legal status
Legal status	CA: Schedule II
Identifiers
IUPAC name Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone
CAS Number	432047-72-8 Y
PubChem CID	9799417
ChemSpider	7975182
UNII	9XRJ6055XT
ChEMBL	ChEMBL244403
CompTox Dashboard (EPA)	DTXSID60430920
Chemical and physical data
Formula	C26H24O2
Molar mass	368.476 g·mol−1
3D model (JSmol)	Interactive image
SMILES c13ccccc1cccc3C(=O)c4ccc(OCCCCC)c2ccccc24
InChI InChI=1S/C26H24O2/c1-2-3-8-18-28-25-17-16-24(21-13-6-7-14-22(21)25)26(27)23-15-9-11-19-10-4-5-12-20(19)23/h4-7,9-17H,2-3,8,18H2,1H3 Key:RSUMDJRTAFBISX-UHFFFAOYSA-N
(verify)

Legal Status

As of October 2015 CB-13 is a controlled substance in China.^[4]

CB-13 is a Schedule I controlled substance in North Dakota.^[5]

See also

• A-PONASA
• AM-6545
• AZ-11713908
• Bunamidine